Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance

Diabetes

Volumn 63, Issue 1, 2014, Pages 300-311

  Nawrocki, Andrea R ^a   Rodriguez, Carlos G ^a   Toolan, Dawn M ^a   Price, Olga ^a   Henry, Melanie ^a   Forrest, Gail ^a   Szeto, Daphne ^a   Keohane, Carol Ann ^a   Pan, Yie ^a   Smith, Karen M ^a   Raheem, Izzat T ^a   Cox, Christopher D ^a   Hwa, Joyce ^a   Renger, John J ^a   Smith, Sean M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[2 (6 CHLOROPYRIDIN 3 YL) 4 [1METHOXYPROPAN 2 YL]OXY N (6 METHYLPYRIDIN 3 YL) 7,8 DIHYDROPYRIDOL[4,3 D]PYRIMIDINE 6(5H) CARBOXAMIDE]; ADIPONECTIN; CHOLESTEROL; CYCLIC GMP; DIZOCILPINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENERGY EXPENDITURE; ENERGY METABOLISM; ENZYME INHIBITION; FEEDING BEHAVIOR; FOOD INTAKE; GENE DELETION; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HYPERINSULINEMIA; HYPOPHAGIA; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LOCOMOTION; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; QUALITY CONTROL; SCHIZOPHRENIA; STEADY STATE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84891811147     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0247     Document Type: Article

References (39)

1. Tsutsumi C, Uchida H, Suzuki T, et al. The evolution of antipsychotic switch and polypharmacy in natural practice-a longitudinal perspective. Schizophr Res 2011;130:40-46
2. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51-57
3. Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther 2004;26:1936-1946
4. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(Suppl. 4):8-13
5. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65(Suppl. 7):4-18; quiz 19-20
6. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520
7. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007;76:481-511
8. Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 2009;202:419-443
9. Fujishige K, Kotera J, Michibata H, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 1999;274:18438-18445
10. Coskran TM, Morton D, Menniti FS, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006;54:1205-1213
11. Seeger TF, Bartlett B, Coskran TM, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res 2003;985:113-126
12. Xie Z, Adamowicz WO, Eldred WD, et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 2006;139:597-607
13. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA. Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase. Gene 1999;234:109-117
14. Soderling SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A 1999;96:7071-7076
15. Siuciak JA, Chapin DS, Harms JF, et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006;51:386-396
16. Siuciak JA, McCarthy SA, Chapin DS, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 2006;51:374-385
17. Grauer SM, Pulito VL, Navarra RL, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 2009;331:574-590
18. Raheem IT, Breslin MJ, Fandozzi C, et al. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg Med Chem Lett 2012;22:5903-5908
19. Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008; 325:681-690
20. Smith SM, Uslaner JM, Cox CD, et al. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology 2013;64:215-223
21. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001;25:633-641
22. Rodefer JS, Murphy ER, Baxter MG. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 2005;21:1070-1076
23. Rodefer JS, Saland SK, Eckrich SJ. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. Neuropharmacology 2012;62:1182-1190
24. Tschöp MH, Speakman JR, Arch JR, et al. A guide to analysis of mouse energy metabolism. Nat Methods 2012;9:57-63
25. Huang W, Zhang Y, Sportsman JR. A fluorescence polarization assay for cyclic nucleotide phosphodiesterases. J Biomol Screen 2002;7:215-222
26. van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-645
27. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001;101:277-288
28. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004;65(Suppl. 18):13-26
29. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110:103-110
30. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006;55:1537-1545
31. Cantin LD, Magnuson S, Gunn D, et al. PDE-10A inhibitors as insulin secretagogues. Bioorg Med Chem Lett 2007;17:2869-2873
32. Heimann E, Jones HA, Resjö S, Manganiello VC, Stenson L, Degerman E. Expression and regulation of cyclic nucleotide phosphodiesterases in human and rat pancreatic islets. PLoS ONE 2010;5:e14191
33. Hoebel BG, Hernandez L, Schwartz DH, Mark GP, Hunter GA. Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. Ann N Y Acad Sci 1989;575:171-191; discussion 192-193
34. Palmiter RD. Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci 2007;30:375-381
35. Salamone JD, Correa M. Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 2002;137:3-25
36. Smith GP, Schneider LH. Relationships between mesolimbic dopamine function and eating behavior. Ann N Y Acad Sci 1988;537: 254-261
37. Palmiter RD. Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice. Ann N Y Acad Sci 2008;1129:35-46
38. Figlewicz DP, Benoit SC. Insulin, leptin, and food reward: update 2008. Am J Physiol Regul Integr Comp Physiol 2009;296:R9-R19
39. Lenard NR, Berthoud HR. Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity (Silver Spring) 2008;16 (Suppl. 3):S11-S22